NASDAQ:TBPH Theravance Biopharma Q4 2025 Earnings Report $15.58 -0.36 (-2.26%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$15.65 +0.07 (+0.45%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Theravance Biopharma EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual Revenue$17.70 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ4 2025Date3/31/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsTheravance Biopharma's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Theravance Biopharma Earnings HeadlinesTheravance Biopharma (NASDAQ:TBPH) Shares Pass Above 50 Day Moving Average - Time to Sell?May 30, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7, 2026 | prnewswire.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 3 at 1:00 AM | Behind the Markets (Ad)Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S. Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In addition to its marketed respiratory franchise, Theravance Biopharma maintains a diversified pipeline with clinical-stage programs in immunology and rare disease. Its immunology efforts include a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases, while its rare disease portfolio features a norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. The company leverages internal research capabilities alongside collaborations and partnerships to advance its small-molecule candidates through clinical and regulatory milestones. Founded in 1998 as part of a respiratory research group of GlaxoSmithKline and later spun out as an independent entity in 2014, Theravance Biopharma is headquartered in South San Francisco, California. It operates research facilities in the Bay Area and maintains corporate offices in Dublin, Ireland, supporting its global clinical programs. The company’s leadership team, under President and Chief Executive Officer Rick E. Winningham, brings deep expertise in pharmaceutical R&D, regulatory affairs and commercial strategy aimed at delivering new therapeutic options to patients worldwide.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointFirstCash Turns Pawn Into a Growth MachineHubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
